Complement-endothelial cell interactions: pathophysiological implications

被引:62
作者
Tedesco, F
Fischetti, F
Pausa, M
Dobrina, A
Sim, RB
Daha, MR
机构
[1] Univ Trieste, Dept Physiol & Pathol, I-34127 Trieste, Italy
[2] Univ Trieste, Inst Internal Med, Trieste, Italy
[3] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England
[4] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands
关键词
D O I
10.1016/S0161-5890(99)90054-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The function of the endothelial cells can be modulated by humoral factors present in the circulation and in the extravascular fluid, including proteins of the complement system. This review examines the multiple interactions between the complement system and the endothelial cells and their functional consequences on inflammation, coagulation and regulation of vascular tone. The implications of these interactions in the induction and progression of the vascular lesions occurring in atherosclerosis, ischemia/reperfusion and xenotransplantation and the possible therapeutic approaches in terms of complement regulation are also discussed. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 75 条
[1]   ACTIVATION OF COMPLEMENT AND KININ SYSTEMS AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A COMPARISON BETWEEN STREPTOKINASE AND RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
AGOSTONI, A ;
GARDINALI, M ;
FRANGI, D ;
CAFARO, C ;
CONCIATO, L ;
SPONZILLI, C ;
SALVIONI, A ;
CUGNO, M ;
CICARDI, M .
CIRCULATION, 1994, 90 (06) :2666-2670
[2]   LIMITATION OF REPERFUSION INJURY BY A MONOCLONAL-ANTIBODY TO C5A DURING MYOCARDIAL-INFARCTION IN PIGS [J].
AMSTERDAM, EA ;
STAHL, GL ;
PAN, HL ;
RENDIG, SV ;
FLETCHER, MP ;
LONGHURST, JC .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (01) :H448-H457
[3]   DECAY-ACCELERATING FACTOR IS PRESENT ON CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS [J].
ASCH, AS ;
KINOSHITA, T ;
JAFFE, EA ;
NUSSENZWEIG, V .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (01) :221-226
[4]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992
[5]   Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads [J].
Berge, V ;
Johnson, E ;
Hogasen, K .
APMIS, 1997, 105 (01) :17-24
[6]   HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS SYNTHESIZE S-PROTEIN (VITRONECTIN) INVITRO [J].
BERGE, V ;
JOHNSON, E ;
HOGASEN, K ;
HETLAND, G .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1992, 36 (01) :119-123
[7]  
BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959
[8]  
BROOIMANS RA, 1989, J IMMUNOL, V142, P2024
[9]  
BROOIMANS RA, 1990, J IMMUNOL, V144, P3835
[10]   CARDIOPROTECTIVE EFFECTS OF A C1 ESTERASE INHIBITOR IN MYOCARDIAL-ISCHEMIA AND REPERFUSION [J].
BUERKE, M ;
MUROHARA, T ;
LEFER, AM .
CIRCULATION, 1995, 91 (02) :393-402